PARSIPPANY, NJ--(Marketwire - December 15, 2009) - The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to one new hire.
The inducement stock options cover 15,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10-year term and vest over four years as follows: 25 percent of these options will vest on the date one year from the optionee's hire date, the remainder will vest in monthly increments during the following 36 months (in all cases subject to the terms and conditions of the Company's 2009 Equity Inducement Plan).
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Medicines Company's website is www.themedicinescompany.com.
Statements contained in this press release about The Medicines Company that
are not purely historical, and all other statements that are not purely
historical, may be deemed to be forward-looking statements for purposes of
the safe harbor provisions under The Private Securities Litigation Reform
Act of 1995. Without limiting the foregoing, the words "believes,"
"anticipates" and "expects" and similar expressions are intended to
identify forward-looking statements. These forward-looking statements
involve known and unknown risks and uncertainties that may cause the
Company's actual results, levels of activity, performance or achievements
to be materially different from those expressed or implied by these
forward-looking statements. Important factors that may cause or contribute
to such differences include whether physicians, patients and other key
decision-makers will accept clinical trial results, whether the Company is
able to develop our global operations and penetrate foreign markets whether
Angiomax can successfully compete with all categories of anticoagulant
drugs and such other factors as are set forth in the risk factors detailed
from time to time in the Company's periodic reports and registration
statements filed with the Securities and Exchange Commission including,
without limitation, the risk factors detailed in the Company's Quarterly
Report on Form 10-Q filed on November 9, 2009, which are incorporated
herein by reference. The Company specifically disclaims any obligation to
update these
forward-looking statements.
